410 Rec'd PCT/PTO 1 7 SEP 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Christophe Marcireau et

Serial No.: 09/744,125

Filed:

January 19, 2001

Title:

MEKK1-INTERACTING FHA

SEP 1 7 2001

PROTEIN (M1F1)

Examiner:

Art Unit:

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

9/13/0)

Signature JAC

LATE SUBMISSION OF DECLARATION UNDER 37 C.F.R. 1.53(f)

Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the "NOTICE TO FILE MISSING PARTS OF APPLICATION - FILING DATE GRANTED" which was mailed on 13 April, 2001 and which indicated that the oath or declaration was missing, Applicants submit herewith the Declaration for the present application and a copy of Form PTO-1533.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment to Account No. 18-1982. Two duplicate copies of this sheet are enclosed.

09/21/2001 SNAJARRO 00000044 181982 09744125

01 FC:154

130.00 CH

Respectfully submitted,

William C. Coppola, Reg. No. 41,686

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-4854 Telefax (908) 231-2626

Docket No. A3233A

Telephone: 703 305-3631

FORM PCT/DO/EO/905 (March 2001)

Commissioner for Patents, Box PCT Jnited States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATIONNO44 125

MAPPET NAMED APPLICANT

5611

ETTY. DOCKET NO. A323:3A

005487 AVENTIS PHARMACEUTICALS, INC. PATENTS DEPARTMENT ROUTE 202-206, P.O. BOX 6800 BRIDGEWATER NJ 08807-0800

INTERNATIONA	L APPLICATION NO.
	- PCT/EP99/05 142
	_

07/21/99

99 07/21/98 04/13/01

DATE MAILED

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

[V	The application fails to comply with the requirements of 37 CFR 1.821-1.825.
F	This application does not contain, a "Sequence Listing" as a separate part of the
	disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c)
Е	A copy of the "Sequence Listing" in computer readable format has not been submitted as
	required by 37 CFR 1.821(e).
· _	A copy of the "Sequence Listing" in computer readable form has been submitted. The
	content of the computer readable form, however, does not comply with the requirements of
	37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw
	Sequence Listing."
	The computer readable form that has been filed with this application has been found to be
	damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A
	substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
لــا	The paper copy or compact disc of the "Sequence Listing" is not the same as the
	computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Other:
L	Outor.
:+:	······································
APPLICA	NT MUST PROVIDE:
	An initial or substitute computer readable form (CRF) of the "Sequence Listing."
$\bar{\Box}$	An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as ar
	amendment directing its entry into the specification.
	A statement that the contents of the paper or compact disc and the computer readable form
	are the same and, where applicable, include no new matter, as required by 37 CFR
	1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
FOR OHE	STIONS DECADDING COMPLIANCE WITH THESE DECLUDENCE OF THE
CALL:	STIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
	03) 308-4216, for Rules interpretation,
(7	103) 308-4212, for CRF submission help,
	(03) 287-0200, for Patentin software help

Barbara Campbell, Paralegal

Telephone: 703 305-3631

FORM PCT/DO/EO/905 (March 2001)

0 347314/	12644	125	MARCIREAL	J.,	:	3 - 1 C		WELSTAD BOY I'I	S
U.S. APPLICATION NO.			PIRST NAMED AF	PPLICANT		ATTY. DO	CKEL NO.	3 3 33A	ω δ
005487 AVENTI		ACEUTICAL		5611	INTERNAT	TONAL APPLICATI	(EP99/0 ой но.	5142	
	S DEPAR			ľ					
		, P.O. BC J 08807-0			I.A. FILINO DA	สย7/2/1/ย	SLOWITY DATE	07/21/	98 ·
•		-					04/13	/01 .	, '
	0515	ianya neol		T INTENEZI	DATE MAII		TOMPTOT	, , õ	í 1. '
NOTIFICATIO	STATES	DESIGNAT	ED/ELECTE	D OFF	ICE (DO/EO/U	US)		چې ش	•
1. The following item	ns have been s a Designated (ubmitted by the Office (37 CFR)	applicant or the l	ected Office	ce (37 CFR 1.495)	and fracema :	<u>"</u>	- ਡ -	
[☑] U.S. Bas	ic National Fe	e.	Indication of	of Small E	ntity Status.		1 2	A	1 #
Copy of	he internation	al application.			rnational application		비 걸었	$\overline{\Omega}$	1 113
	Declaration of		\sim	of Article	19 amendments in	ito English.	فاة	3	1
	Article 19 ame	ndments.	Other:		•			3	
Priority I	national Prelic	ninary Examinal	ion Report in Eng	glish and i	ts Annexes, if any.		DE	9 2	
Translati	on of Annexes	to the Internation	nal Preliminary I	Examinatio	n Report into Engl	lish.	No.	and 1	Ħ ₂
2. Applicant has r	equested early	processing unde	er 35 U.S.C. 371((f) but has	not filed the follow	ving indicated	tems ind/o	1.4	Y 3
the indicated items in	paragraph 3 b	elow. The Basic	National Fee and	d the copy	of the internationa	l application	must be filed	30-4	ر ا ا
prior to 20 or 30 mon	ths from the p ic National Fe		old abandonment Copy of the	i. e internatio	onal application.			30	
3. The following item			,•		•	the requiren	ents for		3
accentance under 35 I	J.S.C. 371:	•					DUE		19
a. Transl	ation of the ap	piication into Ei ropriate 20 or 30	ignsn. A process months from the	nriority d	ll be required if sullate.	onnued .	ă	m	8
The	current trans	ation is defective	e for the reasons	indicated o	on the attached Not	ice of Defec	*	₹₩	A
Tra	inslation.		-1: 6 -1 - -		dos the Asserts	oter than the	9		16
b. Proce	ssing fee for p	roviding the tran	islation of the app the priority date	(37 CFR	nd/or the Annexes I	ater than the	5	出口	二 13
ந்து c. Oath ம	or declaration	of the inventors,	in compliance w	ith 37 CFF	R 1.497(a) and (b),	properly idea	ntienng	목돶;	FIR
the sur	application (p charge will be	referably by the	International app	lication nu	mber and international interna	onal filing dM	(0)		7
dat The	e. e current oath	or declaration de	es not comply w	ith 37 CFI	R 1.497(a) and (b)	for the reason	15		
₹ <u>'</u> a	icated on the a	ttached PCT/DC	D/EO/917.						
. La conom			declaration later	ınan ine ap	propriate 20 or 30	monus nom	ше		,
4 Additional claim (fees of \$	CFR 1.492(e)).	large entity 🖂	small entit	y, including any re	quired multip	de dependen	t	
claim fee, are require due (37 CFR 1.492(g	d. Applicant	must submit the ed PTO-875.	additional claim	fees or car	ncel the additional (claims for wh	ich fees are		
5. Applicant has PCT/DO/EO/920.	not submitted	the required sequ	ence listing purs	uant to 37	CFR 1.821-1.825.	See attache	d		
ALL OF THE ITEM MONTHS FROM T THE PRIORITY D RESPOND WILL F	THE DATE O ATE FOR TI	F THIS NOTIC IE APPLICATI	Œ OR BY 22 OI ON, WHICHEV	R 32 MOI	11H2 (MDere 37 C	JFK 1.495 8P	ipites) rkoi	M	
The time period set a 1.136(a).	above may be	extended by filin	g a petition and f	ee for exte	ension of time unde	er the provision	ns of 37 CF	R	
6. If box 3a or 3c is Annexes will be cand 7. The Article 19 or 30 (37 CFR 1.495	celled. A proc amendments	essing fee will b are cancelled sir	e required if subt ice a translation v	mitted late	r than 20 of 30 mo	nuns from ute	CFR-1.494(5.	
Applicant is reminde address given in the	d that any con	nmunication to the	he United States I application no. sh	Patent and own above	Trademark Office e. (37 CFR 1.5)	must be maile	ed to the		
	A conv o	f this notice	MUST be n	eturnea	with this res	ponse.			
Enclosed: [LAPCT/		. □N	otice of Defective	Translatio	on.				
PTO-	875	Ū,	CT/DO/EO/920		ıra Campbell, P	aralegal			

Barbara Campbell, Paralegal Telephone: 703 305-3631